Humana Inc. (NYSE:HUM) Shares Bought by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. boosted its stake in Humana Inc. (NYSE:HUM - Free Report) by 2.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,672 shares of the insurance provider's stock after buying an additional 1,715 shares during the quarter. Royal London Asset Management Ltd. owned approximately 0.06% of Humana worth $17,169,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of HUM. Pzena Investment Management LLC lifted its position in shares of Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock valued at $915,736,000 after acquiring an additional 1,103,132 shares in the last quarter. Boston Partners lifted its holdings in Humana by 435.8% in the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock valued at $279,236,000 after purchasing an additional 893,637 shares in the last quarter. FMR LLC lifted its holdings in Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider's stock valued at $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Retirement Systems of Alabama boosted its stake in Humana by 735.9% during the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider's stock worth $55,563,000 after purchasing an additional 192,801 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC purchased a new stake in shares of Humana during the third quarter worth $50,102,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the company's stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.37% of the stock is owned by corporate insiders.

Humana Trading Down 1.3 %

Humana stock traded down $3.50 during midday trading on Wednesday, reaching $270.27. 822,577 shares of the stock traded hands, compared to its average volume of 1,605,868. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market cap of $32.62 billion, a PE ratio of 27.16, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a 50-day simple moving average of $270.83 and a two-hundred day simple moving average of $275.00. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Research analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.31%. Humana's dividend payout ratio (DPR) is 35.58%.

Wall Street Analyst Weigh In

HUM has been the topic of a number of recent research reports. Morgan Stanley lowered their price target on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Piper Sandler upped their price target on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research report on Wednesday, January 15th. Royal Bank of Canada reiterated an "outperform" rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Barclays upped their target price on Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. reduced their price target on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a report on Tuesday, February 18th. Eighteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Humana presently has a consensus rating of "Hold" and an average target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.